Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
B3GALT5 Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q9Y2C3 |
|---|---|
| Clone Names | 90826054 |
| Gene ID | 10317 |
|---|---|
| Other Names | Beta-1, 3-galactosyltransferase 5, Beta-1, 3-GalTase 5, Beta3Gal-T5, Beta3GalT5, b3Gal-T5, 241-, Beta-3-Gx-T5, UDP-Gal:beta-GlcNAc beta-1, 3-galactosyltransferase 5, UDP-galactose:beta-N-acetylglucosamine beta-1, 3-galactosyltransferase 5, B3GALT5 |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | B3GALT5 (HGNC:920) |
|---|---|
| Function | Catalyzes the transfer of Gal to GlcNAc-based acceptors with a preference for the core3 O-linked glycan GlcNAc(beta1,3)GalNAc structure. Can use glycolipid LC3Cer as an efficient acceptor. |
| Cellular Location | Golgi apparatus membrane; Single- pass type II membrane protein |
| Tissue Location | Expressed in stomach, jejunum, colon, pancreas, small intestine, testis and gastrointestinal and pancreatic cancer cell lines. Hardly detected in lung, liver, adrenal gland and peripheral blood leukocytes. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene is a member of thebeta-1,3-galactosyltransferase (beta3GalT) gene family. This familyencodes type II membrane-bound glycoproteins with diverse enzymaticfunctions using different donor substrates (UDP-galactose andUDP-N-acetylglucosamine) and different acceptor sugars(N-acetylglucosamine, galactose, N-acetylgalactosamine). Thebeta3GalT genes are distantly related to the Drosophila Brainiacgene and have the protein coding sequence contained in a singleexon. The beta3GalT proteins also contain conserved sequences notfound in the beta4GalT or alpha3GalT proteins. The carbohydratechains synthesized by these enzymes are designated as type 1,whereas beta4GalT enzymes synthesize type 2 carbohydrate chains.The ratio of type 1:type 2 chains changes during embryogenesis. Bysequence similarity, the beta3GalT genes fall into at least twogroups: beta3GalT4 and 4 other beta3GalT genes (beta3GalT1-3,beta3GalT5). This gene encodes the most probable candidate forsynthesis of the type 1 Lewis antigens which are frequently foundto be elevated in gastrointestinal and pancreatic cancers. Theencoded protein is inactive with N-linked glycoproteins andfunctions in mucin glycosylation. Five transcript variants havebeen described which differ in the 5' UTR. All transcript variantsencode an identical protein.
References
Hamshere, M.L., et al. Br J Psychiatry 195(1):23-29(2009)Lin, C.H., et al. Glycobiology 19(4):418-427(2009)Seko, A., et al. Tumour Biol. 30(1):43-50(2009)Mare, L., et al. J. Biol. Chem. 282(1):49-57(2007)Hu, Y.H., et al. BMC Genomics 7, 155 (2006) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
